{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:20:33Z","timestamp":1780615233994,"version":"3.54.1"},"reference-count":60,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007936","name":"International AIDS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>HIVR4P 2024, the 5th HIV Research for Prevention Conference, took place in Lima, Peru, 6\u201310 October 2024. The conference focused on new developments in HIV prevention from basic research to new product development and implementation science.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sessions were assigned to one of five tracks: basic science; pre\u2010exposure prophylaxis (PrEP) and antiretroviral (ARV)\u2010based prevention; vaccines and broadly neutralizing antibodies (bNAbs); applied and implementation science; and other prevention modalities and cross\u2010cutting issues. A team of rapporteurs covered each track and identified conference highlights.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Strategies to elicit bNAb responses by vaccination are advancing to clinical trials, while combination bNAbs show promise as an alternative to ARV\u2010based products. There is promising diversity in the PrEP product pipeline and twice\u2010yearly lenacapavir has demonstrated exceptional efficacy, but barriers to widespread access and implementation remain, compounded by new challenges from the significant policy changes and funding reductions of the new US administration. Innovative ways of delivering PrEP to vulnerable communities that could benefit are being explored and, in some cases, have been successfully implemented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Choice in HIV prevention products and differentiated delivery models that enable clients to select options that meet their preferences and changing needs is essential. Additionally, the involvement of the community throughout the design, implementation and dissemination process is necessary to maximize the impact of HIV prevention. Ensuring equitable access in a rapidly changing context will involve policy changes, partnerships with local organizations and addressing social determinants that impact health outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We are in an era with more tools than ever before to prevent HIV acquisition; now, we need to facilitate collaborations between diverse stakeholders, including researchers, community members, policymakers, healthcare providers and funders. The future of HIV prevention should lie in a holistic approach that respects individual choice, enhances service accessibility and is flexible to meet evolving challenges and opportunities. However, policy changes since the conference ended have profoundly altered the HIV prevention landscape and threaten the advances described in this report.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.70001","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:30:01Z","timestamp":1751419801000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The science at HIVR4P 2024: The era of choice in biomedical HIV prevention"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-5155","authenticated-orcid":false,"given":"Beatriz","family":"Grinsztejn","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz) Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Appay","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-4386","authenticated-orcid":false,"given":"Linda\u2010Gail","family":"Bekker","sequence":"additional","affiliation":[{"name":"Desmond Tutu HIV Centre  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Beyrer","sequence":"additional","affiliation":[{"name":"Duke Global Health Institute Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Donnell","sequence":"additional","affiliation":[{"name":"The Fred Hutchinson Cancer Center Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Tecnol\u00f3gicas Biom\u00e9dicas y Medioambientales, Universidad Nacional Mayor de San Marcos Lima Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-7074","authenticated-orcid":false,"given":"Davina","family":"Canagasabey","sequence":"additional","affiliation":[{"name":"Primary Health Care Program PATH Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz) Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Ganor","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Muturi\u2010Kioi","sequence":"additional","affiliation":[{"name":"IAVI Nairobi Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-8836","authenticated-orcid":false,"given":"Katrina F.","family":"Ortblad","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division Fred Hutchinson Cancer Center Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9563-1822","authenticated-orcid":false,"given":"Erin","family":"Cooney","sequence":"additional","affiliation":[{"name":"Department of International Health Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gast\u00f3n","family":"Devisich","sequence":"additional","affiliation":[{"name":"Research Department Fundaci\u00f3n Hu\u00e9sped Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ellenberg","sequence":"additional","affiliation":[{"name":"Life Sciences, Burnet Institute Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Ghiglione","sequence":"additional","affiliation":[{"name":"CONICET \u2013 Universidad de Buenos Aires, Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA (INBIRS) Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"K'Orimba","sequence":"additional","affiliation":[{"name":"MOSAIC, LVCT Health Nairobi Kenya"},{"name":"IAVI New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6927-9861","authenticated-orcid":false,"given":"Phionah Kibalama","family":"Ssemambo","sequence":"additional","affiliation":[{"name":"Makerere University Johns Hopkins University (MU\u2010JHU) Research Collaboration Kampala Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Tatiana","family":"Ludwig\u2010Barron","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter Kenneth","family":"Mielke","sequence":"additional","affiliation":[{"name":"Department of Surgery Duke University Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranajoy","family":"Mullick","sequence":"additional","affiliation":[{"name":"Antibody Translational Research Program, Translational Health Science and Technology Institute, Virus Research, Therapeutics and Vaccines Faridabad India"},{"name":"IAVI New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Kathini","family":"Muthui","sequence":"additional","affiliation":[{"name":"Biosciences Department KEMRI\u2010Wellcome Trust Research Programme Kilifi Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo D.","family":"Radusky","sequence":"additional","affiliation":[{"name":"Life Sciences, Burnet Institute Melbourne Victoria Australia"},{"name":"Faculty of Psychology Universidad de Buenos Aires Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-7087","authenticated-orcid":false,"given":"Emmanuel","family":"Sendaula","sequence":"additional","affiliation":[{"name":"Monitoring and Evaluation, Reach Out Mbuya Community Health Initiative Kampala Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Raza Haider","family":"Tirmizi","sequence":"additional","affiliation":[{"name":"Dostana Male Health Society Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi V. Matsuno","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Tecnol\u00f3gicas Biom\u00e9dicas y Medioambientales, Universidad Nacional Mayor de San Marcos Lima Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Vega","sequence":"additional","affiliation":[{"name":"Hospital General de Agudos \u201cJuan A. Fern\u00e1ndez\u201d Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Pebody","sequence":"additional","affiliation":[{"name":"IAS Consultant Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Fact Sheet 2024. Global HIV statistics","author":"UNAIDS","year":"2024"},{"key":"e_1_2_11_3_1","unstructured":"MarrazzoJ.HIV prevention: current and future prospects for success.5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_4_1","volume-title":"WHO recommends long\u2010acting cabotegravir for HIV prevention","author":"WHO","year":"2024"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738"},{"key":"e_1_2_11_6_1","unstructured":"GrinsztejnB.Opening session.5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_7_1","unstructured":"BrenchleyJ.Microbiome impact on rectal transmission (SY04).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_8_1","unstructured":"GammonM Carpe EliasS FrempongJ LamE PhelpsM BradyJ et\u00a0al.Linking host sensing of microbiota inflammation and HIV acquisition in the female genital tract (OA2202).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_9_1","unstructured":"KaulR OkechB ParkD BuchananL ShaoZ BagayaB et\u00a0al.Impact of antimicrobials on foreskin HIV susceptibility immunology and bacteria in uncircumcised men from Uganda: a randomized open\u2010label phase I\/II clinical trial (OA2205).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_10_1","unstructured":"ConnorsM.T cell efficacy (avidity and function) (SY08).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_11_1","unstructured":"YangH.HLA\u2010E restricted HIV specific T cell responses (SY08).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_12_1","unstructured":"HuaS BenmezianeK DesjardinsD DimantN Dereuddre\u2010BosquetN RelouzatF et\u00a0al.Dysregulation of intestinal Cx3cr1+ macrophages homeostasis contributes to inflammation and viral persistence in SIV\u2010infected cynomolgus macaques (OA0702).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_13_1","unstructured":"Lorenzo\u2010RedondoR ArifMS ThuruthiyilCT PascoeSS ShaabanMA ThomasY et\u00a0al.Transcriptional microenvironment of persistent SIV tissue reservoirs is associated with tertiary lymphoid organs in the colon and characterized by stress\u2010induced decreased protein synthesis (OA0706LB).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_14_1","unstructured":"EstesJ.From HIV pathogenesis to interventions (SY04).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","unstructured":"EhrenbergP GeretzA IzumiT VolcicM YumL Paquin\u2010ProulxD et\u00a0al.Single\u2010cell analyses reveal that monocyte gene expression impacts HIV\u20101 reservoir size in acutely treated cohorts (OA0703).5th HIV Research for Prevention Conference.Lima Peru.2024.","DOI":"10.1101\/2024.11.12.623270"},{"key":"e_1_2_11_16_1","unstructured":"HaigwoodN OrdonezT PandeyS ReedJ HessellA Van RompayK et\u00a0al.Short\u2010term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART\u2010free viral control in infant rhesus macaques (OA1802).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_17_1","unstructured":"NduatiE.Discovering an HIV vaccine: the quest continues (PL03).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_18_1","unstructured":"WieheK SaundersK StallsV CainD VenkatayogiS Martin BeemJ et\u00a0al.Mutation\u2010guided HIV vaccine design: a strategy for developing boosting immunogens for BnAb induction (OA1202).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_19_1","unstructured":"HahnW ParksKR De RosaS MontefioriD BadenL WalshSR et\u00a0al.Vaccination with a novel fractional escalating dose strategy improves early humoral responses with a novel germline targeting HIV vaccine (426.mod.core\u2010C4b): preliminary results from HVTN 301 (OA1204).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_20_1","unstructured":"MielkeD DunnB KeyesT Stanfield\u2010OakleyS SchmitzbergerL SchusterD et\u00a0al.HIV BG505 SOSIP.664 trimer with 3M\u2010052\u2010AF\/alum induces broad and potent ADCC\u2010mediating antibodies (OA0307LB).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_21_1","unstructured":"MuthuiM MuriukiC KibetC OwuorS SeinY MuemaD et\u00a0al.Characterization of the B\u2010cell repertoire in African populations to inform HIV vaccine design (OA1106).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_22_1","unstructured":"MgodiN.bNAbs\u2010based prevention: still relevant in the time of long\u2010acting PrEP (SY05).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_23_1","unstructured":"ScarlattiG.Baby bNAbs: ensuring an AIDS\u2010free generation (SY05).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_24_1","unstructured":"BarouchD.Improved combination bNAbs\u2014novel approaches (SY05).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_25_1","unstructured":"RouzeauR Silva De AssisT BurtonI ShahinL McKenneyK ChinE et\u00a0al.In vivo protection by a combination of engineered bNAbs against repeated high\u2010dose mixed\u2010SHIV challenges (OA0604).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_26_1","unstructured":"ChawanaTD WalshSR Stranix\u2010ChibandaL ChirenjeZM YuC ZhangL et\u00a0al.Pharmacokinetic interaction assessment of the HIV broadly neutralizing monoclonal antibody VRC07\u2010523ls: a cross\u2010protocol analysis of three phase 1 HIV prevention trials HVTN127\/HPTN087 HVTN130\/HPTN089 and HVTN136\/HPTN092 (OA0606).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_27_1","unstructured":"MielkeD GiorgiEE FairclothK EatonT DunnB ZalaquettA et\u00a0al.A higher proportion of recent compared to historic HIV viruses are resistant to antibody dependent cellular cytotoxicity mediated by monoclonal antibodies (OA1503).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_28_1","unstructured":"KelleyC.Twice\u2010yearly lenacapavir for HIV prevention in cisgender gay men transgender and gender\u2010diverse people: interim analysis result from the PURPOSE 2 study (OA0208).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_29_1","unstructured":"Gallardo\u2010CartagenaJ PhanuphakN NdlovuN LossoMH ClementM LucioVDC et\u00a0al.Global racial ethnic and gender diversity among participants enrolled in the PURPOSE\u20102 trial of lenacapavir for pre\u2010exposure prophylaxis (PrEP) (OA0207).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_30_1","unstructured":"NuttallJ HaddadL PlagianosM KrielW VisserJ SolaiL et\u00a0al.Pharmacokinetic superiority of a 3\u2010month dapivirine vaginal ring (100 mg) compared to the 1\u2010month dapivirine vaginal ring (25 mg) (OA0802LB).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_31_1","unstructured":"MayoA ScheckterR ChinulaL Gati MirembeB MansoorLE MgodiN et\u00a0al.Pregnancy and infant outcomes among individuals exposed to dapivirine ring during the first trimester of pregnancy in the MTN\u2010025\/HOPE open\u2010label extension trial.5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_32_1","unstructured":"MarzinkeM HanscomB HainesD ScarsiK AgyeiY RoseS et\u00a0al.Evaluation of potential pharmacologic interactions between CAB\u2010LA or TDF\/FTC and hormonal contraceptive agents: a tertiary analysis of HPTN 084 (OA2306\u2010).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_33_1","unstructured":"PeetM AgrahariV ChandraN ForsbackA\u2010P Akieh\u2010PirkanniemiM LeinoL et\u00a0al.Development of a long\u2010acting biodegradable hydrogel injectable system for single or multi\u2010purpose prevention of HIV and\/or pregnancy (OA0206).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_34_1","unstructured":"Pons\u2010FaudoaF Di TraniN FacchiI SimeoneA BushmanL MaiJ et\u00a0al.Drug\u2010agnostic transcutaneously\u2010refillable subdermal implant for ultra\u2010long\u2010acting delivery of antiretrovirals for HIV prevention (OA1607LB).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_35_1","unstructured":"BauermeisterJ HendrixC LinW WebsterJ AgwuA AndersonT et\u00a0al.Acceptability of an on\u2010demand single\u2010dose tenofovir rectal douche for HIV pre\u2010exposure prophylaxis in young men (ATN 163) (OA0204).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_36_1","unstructured":"RaccagniAR DiotalleviS LolattoR BruzzesiE CatalanoG MainardiI et\u00a0al.Doxycycline post\u2010exposure prophylaxis (DoxyPEP) real\u2010life effectiveness in a cohort of men who have sex with men in Milan Italy (OA1603).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_37_1","unstructured":"MagnoL.CAB sexual health adolescents and youth and psychosocial wellbeing (SY02).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_38_1","unstructured":"AkomE DjomandG LucasT BhatiaR ArunmozhiA DorwardE et\u00a0al.Infrequent new HIV acquisition among returning pre\u2010exposure prophylaxis clients in PEPFAR 2021\u20132023 (OA0102).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_39_1","unstructured":"Verde HashimC TailorJ ProchazkaM NyagahW WarrenM RodolphM et\u00a0al.Identifying global typologies of HIV PrEP implementation: an analysis of global data using PrEP\u2010to\u2010need ratios and PrEP distribution volumes (OA0104).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_40_1","unstructured":"IrunguE ConlonM SoothoaneR K'OrimbaK NaidooN AkelloC et\u00a0al.PrEP choice for women in Africa: uptake of oral PrEP and PrEP ring (OA2402).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_41_1","unstructured":"KirukiM TzindoliH NiyibeshahoM ChabelaM NkongoaneM MaboaO et\u00a0al.Provider and client perspectives on PrEP choice: quality of PrEP choice and factors influencing its provision in the CATALYST implementation study (A2403).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_42_1","unstructured":"RonoB MogakaF NyerereB RotaG HarringtonE LagatH et\u00a0al.Contraceptive method mix and PrEP choice among young women seeking contraception at retail pharmacies in Kenya (OA2404).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_43_1","unstructured":"MontgomeryE Palanee\u2010PhillipsT AtujunaM HartC ReddyK GillK et\u00a0al.Acceptability adherence preference and safety of placebo long\u2010acting pre\u2010exposure prophylaxis (LA\u2010PrEP) injections and implants for HIV\u2010prevention in South African men: the SAMURAI study (OA0803LB).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_44_1","unstructured":"PoteatT BeauchampG MarzinkeMA Gomez\u2010FelicianoK AkingbadeB BeckJ et\u00a0al.PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_45_1","unstructured":"KhanT LiuA PerlottoS NelsonKL StassekL FangJ et\u00a0al.Overcoming challenges integrating injectable PrEP into care: key strategies from the PILLAR study. (OA0502).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_46_1","unstructured":"NdhlovuA KawangaL PhiriD MusondaM NyumbuM.Long\u2010acting injectable cabotegravir (CAB\u2010LA) pilot implementation at primary healthcare level in resource\u2010limited settings: early real\u2010world evidence from the USAID DISCOVER\u2010Health Project in Zambia (OA0504).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_47_1","unstructured":"ReddyK HaoJ SigcuN DladlaN GovindasamiM MatswakeN et\u00a0al.Home based STI self\u2010testing and diagnosis to trigger PrEP restart among adolescent girls and young women in South Africa (OA1905).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_48_1","unstructured":"GolubS.From shame to support: transforming access through autonomy pleasure and care.5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_49_1","unstructured":"SundaramM.Possibilities and pitfalls: AIS potential in HIV prevention (SY09).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_50_1","unstructured":"HartleyJ KellyS KempS PillayD TanserF RatmannO et\u00a0al.Whole\u2010genome sequencing of HIV in rural Kwa Zulu Natal does not support the role of age\u2010disparate disease transmission underpinning the HIV prevalence gender\u2010gap (OA0806LB).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_51_1","unstructured":"FraserC.State of the science of HIV molecular epidemiology and cluster detection (SY12).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_52_1","unstructured":"BollingerJ.Navigating ethical and policy issues in the application of HIV molecular epidemiology (SY12).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_53_1","unstructured":"AbbateMC SilvaAQ MatosCM RodriguesSFM PinheiroL BarbosaMA et\u00a0al.SPrEP\u2014online PrEP and PEP: the first online platform for access to HIV prophylaxes in Brazil (OA0402).5th HIV Research for Prevention Conference.Lima Peru.2024."},{"key":"e_1_2_11_54_1","unstructured":"ShresthaR.Clinic\u2010integrated mobile health intervention (\u201cJomPrEP\u201d app) to improve uptake of HIV testing and pre\u2010exposure prophylaxis among gay bisexual and other men who have sex with men: results from a randomized controlled trial in Malaysia (OA1707).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_55_1","unstructured":"Palanee\u2010PhillipsT HowettR ReddyK NdlovuN KewL IshmailH et\u00a0al.The impact of expedited partner therapy on repeat STI positivity among adolescent girls and young women using oral PrEP in Johannesburg South Africa (OA0904).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_56_1","unstructured":"MelilloS KasoziD BikokyeW RenquistA TaurasM.A descriptive analysis of rapid response social and legal support activities on HIV prevention service delivery among LGBTQI+ clients in Uganda following passage of the 2023 Anti\u2010Homosexuality Act (OA2102).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_57_1","unstructured":"LynchS ParentiT SrivatsanV SharmaA ParshallC KavanaghM.Age of access policy reform needed for adolescents and PrEP in some sub\u2010Saharan African countries.5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_58_1","unstructured":"GiovencoD MasaR MoodleyR AceroC LucasIL SmithJrM et\u00a0al.Food and housing insecurity among cisgender men who have sex with men in the United States and associations with social behavioural and psychological HIV transmission vulnerabilities (OA1705).5th HIV Research for Prevention Conference. Lima Peru.2024."},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00771-8"},{"key":"e_1_2_11_60_1","volume-title":"FY24 Q4 GHSD\/PEPFAR All Hands Data Review [unpublished internal slide deck]","author":"Global Health Security and Diplomacy USDoS","year":"2024"},{"key":"e_1_2_11_61_1","volume-title":"Emergency humanitarian waiver to foreign assistance pause","author":"The Secretary of State USDoS","year":"2025"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T03:41:27Z","timestamp":1753501287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/jia2.70001"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70001","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70001"}}